Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure
Hisham Dokainish, MD, FACC*,
William A. Zoghbi, MD, FACC,
Nasser M. Lakkis, MD, FACC,
Eunice Ambriz, RN, MPH,
Rajnikant Patel, MD,
Miguel A. Quinones, MD, FACC and
Sherif F. Nagueh, MD, FACC
Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, Texas.
View larger version (31K):
[in a new window]
|
Figure 1 (A) Transmitral early diastolic velocity/tissue Doppler early diastolic annular velocity (E/Ea) in patients with congestive heart failure: Kaplan-Meier event-free survival. (B) B-type natriuretic peptide (BNP) in patients with congestive heart failure: Kaplan-Meier event-free survival. E/Ea = transmitral peak diastolic velocity/tissue Doppler early diastolic mitral annular velocity.
|
|
View larger version (21K):
[in a new window]
|
Figure 2 Clinical algorithm to predict patient outcome using B-type natriuretic peptide (BNP) and tissue Doppler imaging. E/Ea = transmitral peak diastolic velocity/tissue Doppler early diastolic mitral annular velocity.
|
|
|
